2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy - Université de Lorraine
Article Dans Une Revue Heart Rhythm Année : 2019

2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy

1 University of Tennessee Health Science Center & Le Bonheur Children's Hospital
2 UCL - University College of London [London]
3 Boston Children's Hospital
4 Mayo Clinic [Rochester]
5 JHU - Johns Hopkins University
6 USP - Universidade de São Paulo = University of São Paulo
7 Duke University Medical Center
8 IADI - Imagerie Adaptative Diagnostique et Interventionnelle
9 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
10 UCLA - University of California [Los Angeles]
11 Cleveland Clinic
12 UPMC - University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis]
13 Fuwai Hospital
14 University of Arizona
15 The University of Sydney
16 Vanderbilt University Medical Center [Nashville]
17 MUSC - Medical University of South Carolina [Charleston]
18 Hospital Privado Del Sur
19 UBC - University of British Columbia [Canada]
20 University of Texas Southwestern Medical Center [Dallas]
21 University of Colorado Anschutz Medical Campus [Aurora]
22 UNIPV - Università degli Studi di Pavia [Italia] = University of Pavia [Italy] = Université de Pavie [Italie]
23 BIDMC - Beth Israel Deaconess Medical Center [Boston]
24 Institute for Heart and Lung Health [Vancouver, BC, Canada]
25 Nippon Medical School
26 UvA - University of Amsterdam [Amsterdam] = Universiteit van Amsterdam
27 UMCU - University Medical Center [Utrecht]
28 ERN GUARD-Heart - European Reference Network for Rare, Low Prevalence, and Complex Diseases of the Heart
29 CUIMC - Columbia University Irving Medical Center
30 URMC - University of Rochester Medical Center
Dominic Abrams
Milind Desai
  • Fonction : Auteur
Wei Hua
  • Fonction : Auteur
Christopher Mcleod

Résumé

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a broad spectrum of genetic, systemic, infectious, and inflammatory disorders. This designation includes, but is not limited to, arrhythmogenic right/left ventricular cardiomyopathy, cardiac amyloidosis, sarcoidosis, Chagas disease, and left ventricular noncompaction. The ACM phenotype overlaps with other cardiomyopathies, particularly dilated cardiomyopathy with arrhythmia presentation that may be associated with ventricular dilatation and/or impaired systolic function. This expert consensus statement provides the clinician with guidance on evaluation and management of ACM and includes clinically relevant information on genetics and disease mechanisms. PICO questions were utilized to evaluate contemporary evidence and provide clinical guidance related to exercise in arrhythmogenic right ventricular cardiomyopathy. Recommendations were developed and approved by an expert writing group, after a systematic literature search with evidence tables, and discussion of their own clinical experience, to present the current knowledge in the field. Each recommendation is presented using the Class of Recommendation and Level of Evidence system formulated by the American College of Cardiology and the American Heart Association and is accompanied by references and explanatory text to provide essential context. The ongoing recognition of the genetic basis of ACM provides the opportunity to examine the diverse triggers and potential common pathway for the development of disease and arrhythmia.

Dates et versions

hal-03208773 , version 1 (26-04-2021)

Identifiants

Citer

Jeffrey Towbin, William Mckenna, Dominic Abrams, Michael Ackerman, Hugh Calkins, et al.. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16 (11), pp.e301-e372. ⟨10.1016/j.hrthm.2019.05.007⟩. ⟨hal-03208773⟩
29 Consultations
0 Téléchargements

Altmetric

Partager

More